p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

NCT02098343 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Interventions

DRUG: APR-246
DRUG: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Sponsor

Aprea Therapeutics